Drug intelligence / Profile preview

AFYX-005

Development stage: Unknown
Lead developer: AFYX Therapeutics
Modality: Small Molecules
Administration: Topical

Overview

AFYX-005 is a topical patch formulation of the potent corticosteroid clobetasol, developed by AFYX Therapeutics. It utilizes the specialized Rivelin patch technology designed to deliver the drug directly to mucosal surfaces, such as the oral cavity or vulvar region. This localized delivery system aims to provide sustained anti-inflammatory and immunosuppressive effects while minimizing systemic exposure. AFYX-005 is currently being investigated in Phase 2 clinical trials for the treatment of Oral Lichen Planus (OLP) and Vulvar Lichen Sclerosus (VLS), and in Phase 1 for Recurrent Aphthous Stomatitis (RAS).

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on AFYX-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFYX-005.

Explore the full profile